JPMORGAN CHASE & CO - 28 Feb 2025 SCHEDULE 13G/A Report for Revance Therapeutics, Inc. Common Stock, par value $0.001 per share (RVNC)

Filing Manager: JPMORGAN CHASE & CO
Reporting Manager: JPMORGAN CHASE & CO.
Security: Revance Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol: RVNC
Disclosed Ownership: 0 shares
Ownership: 0%
Form type: SCHEDULE 13G/A
Filing time: 06 Mar 2025, 10:52:50 UTC
Date of event: 28 Feb 2025
Previous filing: 11 Feb 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
JPMORGAN CHASE & CO.	0%	0	0	0	Rachel Tsvaygoft	Vice President